About Flagship Biosciences
Flagship Biosciences is a private company based in Broomfield, Colorado. It has reported $11,500,000 raised in four offerings on Form D since March 2018. Its chief executive is Trevor Johnson.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 10, 2024 | Apr 18, 2024 | $5,000,000of $6.3M target | 3 | $1.6M | EquityRule 506(b) | Form D ↗ |
| Nov 27, 2023 | Dec 14, 2023amended Feb 21, 2024 | $3,000,000of $5.0M target | 3 | $1.0M | Debt, Options, Securities on exercise, Convertible Promissory NotesRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 26, 2018 | Jul 9, 2018 | $2,500,000fully sold | 10 | $250K | EquityRule 506(b) | Form D ↗ |
| Jan 9, 2018 | Mar 16, 2018 | $1,000,000fully sold | 9 | $111K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, four offerings | $11,500,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Flagship Biosciences's Form D filed Apr 18, 2024.
Earlier filings also listed Fisher Aaron (director, last listed Sep 2022), Nancy Gillett (director, last listed Jul 2018), L. Northey (cfo, secretary, treasurer, last listed Jul 2018), Joe Kruger (executive officer, last listed Jul 2018), Holger Lange (executive officer, last listed Jul 2018), Gary Clark (director, last listed Jul 2018), G. Young (executive officer, director and promoter, last listed Jul 2018) and Gregory Tucker (director, last listed Mar 2018).